Sumitomo Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Japan · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
6-8 Doshomachi 2-chome, Doshoumachi, Osa...Phone Number
+81 662035321Website
www.sumitomo-pharma.comRevenue
$2.2 BillionStock Symbol
DNPUFIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
1
2
1
1
About Sumitomo Pharma
Sumitomo Pharma seeks to continuously create innovative pharmaceutical products by pursuing R&D activities focused on Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, all the while incorporating cutting-edge technologies. We also seek to contribute to Global Health through our work in the area of Infectious Disease, and furthermore, through our Frontier Business, we are pursuing R&D and commercialization of new healthcare solutions other than pharmaceuticals for addressing social issues which cannot be solved by pharmaceuticals alone.Explore more
Sumitomo Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sumitomo Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Sumitomo Pharma had a recent Job posting/layoffs
Check out if Sumitomo Pharma is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Sumitomo Pharma
Website visits: Recent activity has been detected on your website
Check if Sumitomo Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Sumitomo Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Sumitomo Pharma recently announced quarterly report
Sumitomo Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Sumitomo Pharma launches new products
Recommended Actions
Find VP level buyers at Sumitomo Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
Sumitomo Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sumitomo Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sumitomo Pharma.
Sumitomo Pharma Tech Stack
A closer look at the technologies used by Sumitomo Pharma
Most Recent Scoops
Person-Based
Earnings, Events, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Sumitomo Pharma has more open roles in Medical & Health than it has had at any time in the past 6 months. Areas of expertise include: ICH Guidelines, Trial Master File, Regenerative Medicine, Clinical Program Development, Stem Cell Biology, Clinical Study Reports, and Informed Consent.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Hiring Plans
Sumitomo Pharma News & Media
Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis
– Nuvisertib (TP-3654), an oral investigational highly selective PIM-1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – MARLBOROUGH, Mass., July 30, 2025 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced that the European...Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA®
Rodney Peete joins the Time to Go™ campaign as the newest GEMTESA Go-Getter, alongside wife Holly Robinson Peete, encouraging men and women to speak up about their overactive bladder symptoms and explore treatment options, like GEMTESA® (vibegron) MARLBOROUGH, Mass., June 30, 2025...Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis
– Nuvisertib (TP-3654), an investigational highly selective oral PIM1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – – Nuvisertib demonstrated symptom and spleen responses correlating with cytokine modulation in the preliminary Phase 1/2...Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA’s affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight w
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sumitomo Pharma
Sign Up For FreeTo access detailed company insights
Sumitomo Pharma seeks to continuously create innovative pharmaceutical products by pursuing R&D activities focused on Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, all the while incorporating cutting-edge technologies. We also seek to contribute to Global Health through our work in the area of Infectious Disease, and f... Read More
